Synergism between CpG-Containing Oligodeoxynucleotides and IL-2 Causes Dramatic Enhancement of Vaccine-Elicited CD8+ T Cell Responses

James N. Kochenderfer, Christopher D. Chien, Jessica L. Simpson and Ronald E. Gress
J Immunol December 15, 2006, 177 (12) 8860-8873; DOI: https://doi.org/10.4049/jimmunol.177.12.8860

Abstract

Novel anticancer vaccination regimens that can elicit large numbers of Ag-specific T cells are needed. When we administered therapeutic vaccines containing the MHC class I-presented self-peptide tyrosinase-related protein (TRP)-2180–188 and CpG-containing oligodeoxynucleotides (CpG ODN) to mice, growth of the TRP-2-expressing B16F1 melanoma was not inhibited compared with growth in mice that received control vaccinations. When we added systemic IL-2 to the TRP-2180–188 plus CpG ODN vaccines, growth of B16F1 was inhibited in a CD8-dependent, epitope-specific manner. Vaccines containing TRP-2180–188 without CpG ODN did not cause epitope-specific tumor growth inhibition when administered with IL-2. The antitumor efficacy of the different regimens correlated with their ability to elicit TRP-2180–188-specific CD8+ T cell responses. When we administered TRP-2180–188 plus CpG ODN-containing vaccines with systemic IL-2, 18.2% of CD8+ T cells were specific for TRP-2180–188. Identical TRP-2180–188 plus CpG ODN vaccines given without IL-2 elicited a TRP-2180–188-specific CD8+ T cell response of only 1.1% of CD8+ T cells. Vaccines containing TRP-2180–188 without CpG ODN elicited TRP-2180–188-specific responses of 2.8% of CD8+ T cells when administered with IL-2. There was up to a 221-fold increase in the absolute number of TRP-2180–188-specific CD8+ T cells when IL-2 was added to TRP-2180–188 plus CpG ODN-containing vaccines. Peptide plus CpG ODN vaccines administered with IL-2 generated epitope-specific CD8+ T cells by a mechanism that depended on endogenous IL-6. This is the first report of synergism between CpG ODN and IL-2. This synergism caused a striking increase in vaccine-elicited CD8+ T cells and led to epitope-specific antitumor immunity.

T cells specific for tumor-associated Ags inhibit tumor growth in many murine models (1, 2, 3), and evidence exists that Ag-specific T cells can cause regression of cancer in humans (4). Peptide vaccines have been extensively used in clinical trials to elicit CD8+ T cells specific for tumor-associated Ags (5, 6, 7, 8). Unfortunately, the magnitude of T cell responses elicited by peptide vaccines in most clinical trials has been modest, and objective clinical tumor responses attributable to peptide vaccines have been rare (5, 6). Improved approaches to therapeutic vaccination are needed to generate potent T cell responses that can consistently cause regressions of malignancy.

Oligodeoxynucleotides (ODN)3 that contain unmethylated CpG motifs (CpG ODN) have been shown to enhance T cell responses in murine peptide vaccination models (3, 9, 10, 11). In a recent clinical trial, vaccines consisting of an immunogenic peptide from the Melan-A melanoma-associated protein emulsified in IFA with CpG ODN were shown to elicit CD8+ T cell responses that were dramatically larger than those elicited by vaccination without CpG ODN (12). CpG ODN have many effects that may be important in enhancing vaccine responses such as increasing expression of costimulatory molecules on APCs and increasing production of many cytokines including IL-6 (13, 14). CpG ODN can make conventional T cells resistant to the suppressive effects of T regulatory cells (Tregs) by an IL-6-dependent mechanism (15).

Although IL-2 promotes proliferation of Ag-specific T cells in vitro (16), the efficacy of exogenous IL-2 at enhancing vaccine-elicited T cell responses in vivo is less clear. Exogenous IL-2 can enhance T cell responses to both acute and chronic viral infections, but this enhancement is critically dependent on the timing of IL-2 administration (17). When vaccine responses have been measured by quantitative ex vivo assays in mouse models, exogenous IL-2 usually produces a modest increase in the number of vaccine-elicited, Ag-specific T cells (1, 18, 19, 20, 21). When IL-2 has been combined with peptide vaccines in clinical trials, increased peptide-specific T cell responses compared with vaccination without IL-2 have not been detected (5, 22). Despite a modest effect at increasing the number of vaccine-elicited CD8+ T cells, IL-2 has been shown to enhance the antitumor activity of vaccination regimens in murine models. In murine tumor therapy models, the combination of dendritic cell vaccines and IL-2 has been shown to be more effective than dendritic cell vaccines alone (23, 24). When mice were treated with a regimen that included vaccination and adoptive transfer of tumor-Ag-specific T cells, exogenous IL-2 was essential for antitumor activity despite the fact that IL-2 minimally increased the number of tumor-Ag specific CD8+ T cells in the peripheral blood (1).

Given the known effectiveness of CpG ODN as a vaccine adjuvant (3, 9, 10, 11), and the ability of IL-2 to cause T cell proliferation and to enhance the efficacy of antitumor vaccines in murine models (1, 16, 23, 24), we hypothesized that peptide plus CpG ODN vaccines would be more effective at eliciting Ag-specific CD8+ T cell responses and at mediating therapeutic antitumor responses if they were combined with exogenous IL-2. As a rigorous test of the vaccination regimens used in our experiments, we used B16F1, a rapidly growing murine melanoma that expresses very low levels of MHC class I molecules and is poorly immunogenic (25). B16F1 expresses tyrosinase-related protein-2 (TRP-2). Because TRP-2 is also expressed by normal melanocytes, it is subject to self-tolerance (26). Amino acids 180–188 of TRP-2 (TRP-2180–188) form an immunogenic MHC class I-presented epitope (2, 3, 26). We found that synergism between IL-2 and CpG ODN led to massive epitope-specific CD8+ T cell responses, and vaccines containing TRP-2180–188 plus CpG ODN in IFA could only mediate epitope-specific antitumor immunity when combined with IL-2. The antitumor effect of TRP-2180–188 plus CpG ODN-containing vaccines combined with IL-2 was dependent on CD8+ T cells. Our results demonstrated that generation of CD8+ T cell responses by peptide plus CpG ODN-containing vaccines administered with exogenous IL-2 depended on endogenous IL-6.

Materials and Methods

Mice and tumor cells

C57BL/6 and BALB/c mice were obtained from the National Cancer Institute (Frederick, MD) animal production area. IL-6-deficient mice (27) on a C57BL/6 background were obtained from The Jackson Laboratory. Type I IFNR-deficient mice on a BALB/c background were provided by Dr. H. Young (National Cancer Institute, Frederick, MD). These mice were derived from type I IFNR-deficient mice on a 129 SvEv background (28) by Dr. J. Durbin (Ohio State University, Columbus, OH). The genotype of these mice was confirmed by PCR (data not shown). All animal studies were approved by the National Cancer Institute Center for Cancer Research Animal Care and Use Committee. The B16F1 melanoma (H-2b) and EL4 lymphoma cells (H-2b) were purchased from American Type Culture Collection. The TC-1 fibroblast tumor cell line (H-2b) (29) was provided by T. C. Wu (Johns Hopkins University, Baltimore, MD).

Vaccine ingredients

Amino acids 180–188 of TRP-2 (TRP-2180–188) (2, 3, 26), amino acids 257–264 of the OVA protein (OVA257–264) (10), amino acid 366–374 of the influenza A nucleoprotein (NP366–374) (1), amino acids 82–90 of the RSV (respiratory syncytial virus) M2 protein (RSV M282–90) (30), amino acids 25–33 of the human gp100 protein (gp10025–33) (1), and amino acids 197–205 of the HIV gag protein (gag197–205) (31) and amino acids 49–57 of the human papillomavirus E7 protein (E749–57) (11) form immunogenic epitopes that are presented by MHC class I molecules. Peptides with cell-penetrating peptide moieties (CPP) can penetrate dendritic cell membranes and elicit T cell responses (32). We used a peptide made up of a cell-penetrating moiety and TRP-2180–188 (CPP-TRP-2) in our work (32). Amino acids 128–140 of the hepatitis B core protein (HBC128–140) form an epitope presented by H-2 I-Ab that can elicit CD4+ T cell responses that are capable of enhancing vaccine-elicited CD8+ T cell responses (33). Peptides were synthesized and purified to >95% purity by Biopeptide or New England Peptide. Human recombinant IL-2 was obtained from the National Cancer Institute Biological Resources Branch. A sterile, endotoxin-free solution of CpG ODN 1826 (CpG ODN) (14) in Tris-EDTA buffer was purchased from Coley Pharmaceutical Group. IFA was purchased from Sigma-Aldrich.

Vaccine preparation

Each priming vaccine in experiments that used ΤRP-2180–188 or OVA257–264 consisted of the following ingredients emulsified in IFA: 50 μg of CpG ODN, 50 μg of ΤRP-2180–188 or OVA257–264, and, in some experiments, 60 μg of HBC128–140. Boost vaccines were prepared in an identical manner as priming vaccines except 100 μg of ΤRP-2180–188 or OVA257–264 was included. In experiments in which the HBC128–140 peptide was used, 120 μg of HBC128–140 was included in boost vaccinations. All E749–57 vaccine doses consisted of 50 μg of CpG ODN and 50 μg of E749–57 in IFA. All RSV M282–90 vaccine doses consisted of 50 μg of CpG ODN and 50 μg of RSV M282–90 in a PBS/IFA emulsion. All CPP-TRP-2 vaccine doses consisted of 50 μg of CpG ODN and 100 μg of CPP-TRP-2 in a PBS/IFA emulsion. The volume of all vaccine injections was 100 μl. When CpG ODN was eliminated in experiments, it was replaced with Tris-EDTA buffer. When IL-2 was given, 40,000 IU was administered i.p. twice daily. When IL-2 was not administered, control buffer, containing human serum albumin and mannitol in PBS, was injected in place of IL-2 as a control. In all experiments, priming vaccinations were given as a series of three injections with 3 days between injections. The first and third priming vaccines were given s.c. at the base of the tail; the second priming vaccination was administered s.c. on the left side. Boost vaccinations were given at the base of the tail s.c.

Antibodies

The following Abs from BD Pharmingen were used: anti-CD3ε (clone 145-2C11), anti-IFN-γ (clone XMG1.2), anti-I-A/I-E (clone 2G9), anti-Ly6G (clone RB6-8C5), anti-CD28 (clone 37.51), and anti-CD16/CD32 (clone 2.4G2). Anti-CD8α (clone CT-CD8a) from Caltag Laboratories was used.

Peptide stimulation followed by intracellular cytokine staining (ICCS) experiments

The percentage of CD8+ T cells specific for ΤRP-2180–188 was determined by stimulating splenocytes with peptides followed by ICCS. Mice were sacrificed, splenocytes were RBC depleted, washed, and suspended at 3.5 × 106 live cells/ml. For each mouse, two 15-ml tubes were prepared. Each tube contained 3.5 × 106 splenocytes, 2 μg/ml of a stimulatory anti-CD28 Ab, and 1 μl of Golgi Plug (BD Pharmingen). For each mouse, 20 μg/ml ΤRP-2180–188 was added to one tube and 20 μg/ml of the negative control peptide OVA257–264 was added to the other tube. All tubes were incubated at 37°C for 6 h. The cells were then washed and surface stained for CD3 and CD8. The cells were then permeabilized with Cytofix/Cytoperm and stained for intracellular IFN-γ according to the instructions of the Cytofix/Cytoperm kit (BD Pharmingen). Flow cytometry acquisition was performed with a BD Biosciences FACsort. Analysis was performed with CellQuest software (BD Biosciences). For each mouse, a tube containing cells stimulated with ΤRP-2180–188 and another tube containing cells stimulated with OVA257–264 were analyzed. The percentage of CD8+ T cells specific for ΤRP-2180–188 was calculated as the percentage of CD3+CD8+IFN-γ+ events with ΤRP-2180–188 stimulation minus the percentage of CD3+CD8+IFN-γ+ events with OVA257–264 stimulation. ICCS assays to measure RSV M282–90-specific responses were performed in an identical manner except for the substitution of RSV M282–90 for TRP-2180–188 and gag197–205 for OVA257–264. ICCS assays to measure E749–57-specific responses were also performed in an identical manner except for the substitution of E749–57 for TRP-2180–188 and NP366–374 for OVA257–264. Anti-CD28 was used in all ICCS experiments except those reported in Fig. 9⇓D. ICCS assays of peripheral blood cells were performed in the same manner as for splenocytes except that 1 × 106 peripheral blood cells were used in each tube instead of 3.5 × 106 splenocytes.

Quantitation of the absolute number of splenic CD8+ T cells specific for ΤRP-2180–188 in ICCS experiments

RBC-depleted splenocytes from vaccinated mice were prepared. Trypan blue was used for dead cell discrimination and live cells were counted. The cells were then stained with anti-CD3 and anti-CD8 and suspended in PBS. 7-Aminoactinomycin D (7-AAD; BD Pharmingen) was added for dead cell exclusion. A region enclosing all live cells was analyzed for dual expression of CD3 and CD8. The percentage of live cells expressing both CD3 and CD8 was multiplied by the total number of live splenocytes to determine the absolute number of splenic CD3+CD8+ cells. The absolute number of splenic ΤRP-2180–188-specific CD8+ T cells was determined by multiplying the absolute number of CD3+CD8+ splenocytes by the percentage of CD8+ T cells specific for ΤRP-2180–188 determined during the ICCS assay.

Measurement of CD8+ T cell avidity

To measure the avidity of vaccine-elicited CD8+ T cells, EL4 cells were incubated with either 10, 0.01, 0.001, or 0 μM TRP-2180–188 peptide for 3 h. The EL4 cells were then washed and incubated with splenocytes from vaccinated mice for 5 h. Following the incubation, CD8+ T cells producing IFN-γ were enumerated by ICCS assay as described above. For these assays, an equal number of splenocytes from four mice in each vaccination category were combined and the percentage of CD8+ T cells that were TRP-2180–188-specific was defined as the percentage of CD8+ T cells producing IFN-γ after stimulation with EL4 cells pulsed with a given concentration of TRP-2180–188 peptide minus the percentage of CD8+ T cells producing IFN-γ in response to unpulsed EL-4 cells.

Quantitation of CD8+ T cell responses with MHC class I multimers

To measure TRP-2180–188-specific or OVA257–264-specific CD8+ T cell responses, single-cell suspensions of splenocytes were stained with either TRP-2180–188-Kb or OVA257–264-Kb tetramers (both from Coulter) along with anti-CD8 (clone KT15; Coulter), anti-I-A/I-E, anti-Ly6G, and 7-AAD. To measure RSV M282–90-specific CD8+ T cell responses, we stained splenocytes with RSV M282–90-Kd pentamers (Proimmune). The splenocytes were then stained with anti-CD8 (clone KT15; Coulter), anti-I-A/I-E, anti-Ly6G, and 7-AAD. Analysis of CD8+multimer+ events was performed after first excluding 7-AAD+, I-A+, and Ly6G+ events by gating. Cells from mice that received irrelevant control peptide plus CpG ODN-containing vaccines and IL-2 were stained with the appropriate multimer in each experiment. NP366–374 served as the irrelevant control peptide in experiments in which TRP-2180–188-specific responses were measured, human gp10025–33 served as the irrelevant control peptide in experiments in which OVA257–264-specific responses were measured, and gag197–205 served as the irrelevant control peptide in experiments in which RSV M282–90-specific responses were measured. The fraction of CD8+ splenocytes that were TRP-2180–188 specific, OVA257–264 specific, or RSV M282–90 specific was calculated by subtracting the mean percentage of CD8+ splenocytes from irrelevant control-vaccinated mice that bound multimer in each experiment from the percentage of CD8+ splenocytes from each TRP-2180–188-vaccinated, OVA257–264-vaccinated, or RSV M282–90-vaccinated mouse that bound multimer. The absolute number of epitope-specific CD8+ splenocytes was calculated by multiplying the fraction of live splenocytes that were TRP-2180–188-specific, OVA257–264-specific, or RSV M282–90-specific CD8+ lymphocytes by the number of live splenocytes in each mouse.

Tumor therapy experiments

B16F1 cells were rapidly proliferating with a viability of >95% at the time of injection. The cells were kept on ice and mixed well before each injection. Mice were injected with either 100,000 (see Figs. 1⇓ and 3⇓) or 30,000 (see Figs. 4⇓ and 7⇓) tumor cells s.c. on the right side. For each tumor therapy experiment, mice were injected with tumor cells and then randomly distributed to either the treatment group or the control group. Mice then received vaccination regimens that included either ΤRP-2180–188 (treatment group) or OVA257–264 (control group). In tumor therapy experiments using the TC-1 tumor cell line, mice were injected with 50,000 tumor cells s.c. on the right side 3 days before the initiation of vaccination regimens. The mice then received vaccination regimens as described in Results. Tumor size was measured with calipers every 3 days starting 10–13 days after tumor injection. The longest length and the length perpendicular to the longest length were multiplied to obtain the tumor size (area) in mm2. When the tumor size reached 200 mm2 or ulceration developed, the mice were sacrificed. Some experiments assessed therapy of B16F1 in mice that had been depleted of CD8+ cells. Five hundred micrograms of the anti-CD8 Ab 2.43 (obtained from the National Cell Culture Center) were injected on days −3, −2, −1, 6, and 14 with day 0 being the day of tumor injection and initiation of vaccination. This regimen eliminated >99% of CD3+CD8+ splenocytes. In experiments that used 2.43 for CD8 depletion, a control group was included that received injections of ChromPure rat IgG (Jackson ImmunoResearch Laboratories) in place of 2.43.

FIGURE 1.
FIGURE 1.

Vaccines containing TRP-2180–188, HBC128–140, and CpG ODN in IFA can inhibit growth of the TRP-2-expressing B16F1 melanoma in an epitope-specific manner only when IL-2 is provided. A, Mice were injected with B16F1 melanoma on day 0. Priming vaccinations containing peptides plus CpG ODN were given on days 0, 3, and 6. A boost vaccination was administered on day 14. One group received vaccines containing TRP-2180–188 and another group received vaccines containing the negative control peptide OVA257–264. Aside from the different peptides, the two groups were treated identically. There was not a statistically significant difference in tumor size when TRP-2180–188-vaccinated mice were compared with OVA257–264-vaccinated mice (TRP-2180–188-vaccinated n = 12, OVA257–264-vaccinated n = 11). B, B16F1 was injected and mice were vaccinated in the same manner as in A. IL-2 was administered on days 7–10 and on days 15–18. Tumor size was smaller in TRP-2180–188-vaccinated mice compared with OVA257–264-vaccinated mice. A statistically significant difference (p < 0.002) between the two groups occurred at the indicated (∗) time points (TRP-2180–188-vaccinated n = 14, OVA257–264-vaccinated n = 16). C, Mice received vaccinations and IL-2 as described in B except that CpG ODN was omitted. There was no difference in tumor growth rate when mice receiving TRP-2180–188-containing vaccines were compared with mice receiving vaccines containing the negative control peptide OVA257–264 (TRP-2180–188-vaccinated n = 13, OVA257–264-vaccinated n = 12).

Statistical analysis

Groups were compared using the two-tailed Mann-Whitney U test. In cases where four groups are compared (see Figs. 2⇓, D and E, and 4⇓, A and B), p < 0.01 should be considered statistically significant in accordance with the Bonferroni correction. In all other cases, p < 0.05 should be considered statistically significant. In all graphs, the mean and the SEM are shown. Unless otherwise stated, two to three experiments of each type were conducted and the results of all experiments were combined for graphical presentation and statistical analysis.

FIGURE 2.
FIGURE 2.

A, Vaccines containing TRP-2180–188 and CpG ODN elicit large TRP-2180–188-specific CD8+ T cell responses when administered with IL-2. On days 0, 3, and 6 priming vaccines consisting of TRP-2180–188, HBC128–140, and CpG ODN in IFA were administered. IL-2 was administered on days 7–9. On day 14, a boost vaccine was administered and IL-2 was given on days 15–18. On day 19, the mice were sacrificed, splenocytes were stimulated ex vivo for 6 h with either TRP-2180–188 or the negative control peptide OVA257–264, and intracellular staining for IFN-γ was performed (ICCS assay). Robust TRP-2180–188-specific CD8+ T cell responses, but minimal OVA257–264-specific responses, were detected in a mouse that received TRP-2180–188-containing vaccines. Plots are gated on CD3+ lymphocytes. The percentage of CD3+CD8+ cells that produced IFN-γ is shown on each plot. B, When mice were treated as described in A, a mean of 18.3% of CD3+CD8+ splenocytes produced IFN-γ in response to TRP-2180–188 stimulation, but only 0.1% of CD3+CD8+ splenocytes produced IFN-γ in response to OVA257–264 stimulation (n = 11 mice/group). Synergism between IL-2 and CpG ODN increases the magnitude of TRP-2180–188-specific CD8+ T cell responses. C, Examples are shown of TRP-2180–188-specific CD8+ T cell responses in mice that received either the vaccination regimen described in A consisting of TRP-2180–188, HBC128–140, and CpG ODN in IFA combined with systemic IL-2 or this regimen with CpG ODN but without IL-2 or with IL-2 but with CpG ODN omitted. The ICCS assay was performed as in A. The percentage of CD3+CD8+ cells that produced IFN-γ is shown on each plot. D, Mice received either the vaccination regimen described in A consisting of TRP-2180–188, HBC128–140, and CpG ODN in IFA administered with systemic IL-2, or regimens with IL-2 or CpG ODN omitted. TRP-2180–188-specific CD8+ T cell responses were measured by ICCS assay as in 2A. Regimens containing both CpG ODN and IL-2 elicited larger TRP-2180–188-specific CD8+ T cell responses as a percentage of total CD3+CD8+ splenocytes than regimens containing CpG ODN without IL-2, regimens containing IL-2 without CpG ODN, or regimens containing only peptides in IFA with neither CpG ODN nor IL-2 (n = 8–12/group). E, In the same mice described in D, vaccination regimens containing both CpG ODN and IL-2 generated a larger absolute number of TRP-2180–188-specific CD3+CD8+ splenocytes than regimens containing CpG ODN without IL-2, regimens containing IL-2 without CpG ODN, or regimens containing only peptides in IFA with neither CpG ODN nor IL-2 (n = 8–12/group).

Results

Vaccines containing TRP-2180–188 and CpG ODN can inhibit growth of B16F1 only when exogenous IL-2 is provided

In preliminary experiments, we confirmed that vaccines containing TRP-2180–188, HBC128–140, and CpG ODN in IFA were consistently capable of eliciting CD8+ T cell responses against TRP-2180–188. Because we were interested in studying CD8+ T cell responses, we designed our tumor therapy experiments to detect epitope-specific differences in tumor growth. We injected two groups of mice with the TRP-2-expressing melanoma B16F1. We administered vaccines consisting of TRP-2180–188, CpG ODN, and HBC128–140 emulsified in IFA to one of the groups, and we administered vaccines containing the same ingredients, except that a negative control peptide, OVA257–264, replaced TRP-2180–188, to the second group. Aside from the different peptides, both groups were treated identically. Tumor growth was not inhibited by vaccination with TRP-2180–188 compared with vaccination with OVA257–264 (Fig. 1⇑A). In contrast, when we added IL-2 to the same peptide plus CpG ODN vaccination regimen, epitope-specific inhibition of B16F1 growth occurred (Fig. 1⇑B). Although CpG ODN is known to inhibit growth of B16F1 as a single agent (14), all of our experiments were performed by vaccinating one group of mice with vaccines containing TRP-2180–188 plus CpG ODN and simultaneously vaccinating a second group with vaccines containing OVA257–264 plus CpG ODN. Because both groups were treated identically aside from the difference in peptide, the difference in tumor growth between mice that received vaccines containing TRP-2180–188 and those that received vaccines containing OVA257–264 could be concluded to be epitope specific and not due to the activation of non-epitope-specific effector cells such as NK cells. Both CpG ODN and IL-2 were required for epitope-specific tumor growth inhibition, because epitope-specific tumor growth inhibition did not occur when mice were vaccinated with TRP-2180–188 in IFA without CpG ODN and given IL-2 (Fig. 1⇑C). Because the tumor growth inhibition observed with TRP-2180–188 plus CpG ODN vaccination combined with IL-2 was epitope specific, we hypothesized that IL-2 caused an increase in TRP-2180–188- specific CD8+ T cells.

Synergism between CpG ODN and IL-2 leads to a striking enhancement of TRP-2180–188-specific CD8+ T cell responses

Administration of vaccines consisting of TRP-2180–188, HBC128–140, and CpG ODN in IFA combined with systemic IL-2 resulted in large CD8+ T cell responses that were specific for TRP-2180–188 (Fig. 2⇑A). In mice vaccinated with TRP-2180–188 plus CpG ODN-containing vaccines and given IL-2, a mean of 18.3% of CD3+CD8+ splenocytes produced IFN-γ after a 6-h ex vivo peptide stimulation with TRP-2180–188, but only 0.1% of CD3+CD8+ splenocytes produced IFN-γ in response to the negative control peptide OVA257–264; therefore, the mean TRP-2180–188-specific CD8+ T cell response was 18.2% of CD3+CD8+ splenocytes (Fig. 2⇑B). Naive mice tested with the same assay had 0.01% of CD3+CD8+ splenocytes specific for TRP-2180–188 (data not shown). To assess the roles of IL-2 and CpG ODN in the vaccination regimen, we eliminated either IL-2 or CpG ODN from the regimen of TRP-2180–188 plus CpG ODN-containing vaccines administered with systemic IL-2. When control injections were administered in place of IL-2, a mean TRP-2180–188-specific CD8+ T cell response of only 1.1% of CD3+CD8+ splenocytes was elicited (Fig. 2⇑, C and D). Mice that received vaccines containing TRP-2180–188 plus CpG ODN combined with IL-2 had a mean absolute number of 5.6 × 106 TRP-2180–188-specific CD3+CD8+ splenocytes. Mice that were vaccinated identically, but did not receive IL-2 had a mean of only 0.2 × 106 TRP-2180–188-specific CD3+CD8+ splenocytes (Fig. 2⇑E). When CpG ODN was omitted from the vaccine regimen, but IL-2 was administered, a response was elicited in which 2.8% of CD3+CD8+ splenocytes were specific for TRP-2180–188, and the absolute number of CD3+CD8+ TRP-2180–188- specific splenocytes was 0.5 × 106 (Fig. 2⇑, C–E).

B16F1 tumor-bearing mice generate TRP-2180–188-specific CD8+ T cell responses only when vaccinated against TRP-2180–188 despite having tumors that express the TRP-2 protein

Vaccination of tumor-bearing mice with TRP-2180–188 plus CpG ODN-containing vaccines administered with systemic IL-2 elicited strong TRP-2180–188-specific CD8+ T cell responses. Tumor-bearing mice that received identical regimens except for the replacement of TRP-2180–188 by OVA257–264 did not generate a TRP-2180–188-specific response despite the presence of large B16F1 tumors that expressed TRP-2. (Fig. 3⇓). B16F1 was confirmed to express mRNA for TRP-2 by RT-PCR (our unpublished data).

FIGURE 3.
FIGURE 3.

Tumor-bearing mice generated CD8+ T cell responses against the tumor-associated peptide TRP-2180–188 only when vaccines included TRP-2180–188 and not when vaccines contained the control peptide, OVA257–264, despite the presence of tumors that expressed the TRP-2 protein. A, Mice were vaccinated with peptide plus CpG ODN-containing vaccines and received IL-2 as described in Fig. 1⇑B. One group was vaccinated with TRP-2180–188-containing vaccines and another group was vaccinated with OVA257–264-containing vaccines. Both groups had B16F1 injected on the same day as the first vaccination (day 0). On day 25, when all mice had palpable tumors, mice were sacrificed, splenocytes were stimulated for 6 h with either TRP-2180–188 or OVA257–264, and ICCS was performed. An example of CD8+ T cell responses after ex vivo TRP-2180–188 stimulation of splenocytes from tumor-bearing TRP-2180–188-vaccinated mice is shown. Examples are also shown of CD8+ T cell responses after ex vivo stimulation with TRP-2180–188 or OVA257–264 of splenocytes from tumor-bearing OVA257–264-vaccinated mice. Plots are gated on CD3+ lymphocytes. The percentage of CD3+CD8+ cells that produced IFN-γ is shown on each plot. B, Tumor-bearing TRP-2180–188-vaccinated and OVA257–264-vaccinated mice were treated as in A. TRP-2180–188-specific CD8+ T cell responses were measured by ICCS assay as in A (TRP-2180–188-vaccinated n = 5; OVA257–264-vaccinated n = 4). This was one of three experiments with similar results.

In experiments described so far, HBC128–140, a peptide that can elicit CD4+ T cell responses that are capable of enhancing vaccine-elicited CD8+ T cell responses (33), was included in all peptide plus CpG ODN vaccines. To assess the importance of HBC128–140 as a vaccine component, we vaccinated mice using TRP-2180–188 plus CpG ODN in IFA vaccines without including HBC128–140 and administered IL-2. The mean TRP-2180–188-specific CD8+ T cell response elicited by this regimen made up 32.1% of total CD8+ T cells (Fig. 4⇓A). Synergism between CpG ODN and IL-2 was evident because when IL-2 was omitted from the vaccination regimen TRP-2180–188-specific CD8+ T cells made up only 1.5% of total CD8+ T cells, and when CpG ODN was omitted from the vaccination regimen TRP-2180–188-specific CD8+ T cells made up only 1.1% of total CD8+ T cells. When both IL-2 and CpG ODN were omitted, TRP-2180–188-specific CD8+ T cells made up only 0.1% of total CD8+ T cells (Fig. 4⇓A). The mean absolute number of TRP-2180–188-specific CD8+ T cells increased by 221-fold when IL-2 was added to TRP-2180–188 plus CpG ODN in IFA vaccines (Fig. 4⇓B). We found that the IL-2 administration schedule used in all of the experiments reported in this work, which consisted of moderate dose i.p. IL-2 administered after vaccinations, was superior to low-dose s.c. IL-2 administered at the same time as vaccinations at increasing TRP-2180–188-specific CD8+ T cell responses (data not shown). Tumor therapy experiments demonstrated that TRP-2180–188 plus CpG ODN in IFA vaccines without HBC128–140 mediated epitope-specific tumor growth inhibition when administered with systemic IL-2 (Fig. 4⇓C). Taken together, these data demonstrated that the HBC128–140 was not necessary for generation of large TRP-2180–188-specific CD8+ T cell responses or for epitope-specific tumor growth inhibition by TRP-2180–188 plus CpG ODN in IFA vaccines combined with systemic IL-2; therefore, the remainder of our experiments were conducted without HBC128–140 unless otherwise noted.

FIGURE 4.
FIGURE 4.

An MHC class II-presented helper epitope is not required for synergism between CpG ODN and IL-2 to generate large TRP-2180–188-specific CD8+ T cell responses that cause epitope-specific antitumor immunity. A, Mice were vaccinated with TRP-2180–188 in IFA with or without CpG ODN on days 0, 3, 6, and 14. The mice received IL-2 or control injections on days 7–9 and 15–18. On day 19, TRP-2180–188-specific CD8+ T cell responses were measured by ICCS assay (n = 8–10 mice/group). Vaccines containing both CpG ODN and IL-2 elicited larger TRP-2180–188-specific CD8+ T cell responses as a percentage of total CD3+ CD8+ splenocytes than regimens containing CpG ODN without IL-2, regimens containing IL-2 without CpG ODN, or regimens containing TRP-2180–188 in IFA with neither CpG ODN nor IL-2 (n = 8–10/group). B, In the same mice described in A, vaccination regimens containing both CpG ODN and IL-2 generated a larger absolute number of TRP-2180–188-specific CD3+CD8+ splenocytes than regimens containing CpG ODN without IL-2, regimens containing IL-2 without CpG ODN, or regimens containing TRP-2180–188 in IFA with neither CpG ODN nor IL-2 (n = 8–10/group). C, Mice were injected with 30,000 B16F1 cells on day 0. Mice were vaccinated with peptide plus CpG ODN in IFA vaccines and IL-2 was administered as described in A starting on day 0. One group received vaccines containing TRP-2180–188 and another group received vaccines containing the negative control peptide OVA257–264. Aside from the different peptides, both groups were treated identically. There was a statistically significant difference (p < 0.006) at the indicated (∗) time points (n = 12 mice/group). D, The antitumor effect observed with TRP-2180–188 plus CpG ODN in IFA vaccines administered with IL-2 is dependent on CD8+ cells. Mice were Ab depleted of CD8+ cells or treated with isotype-matched control Abs. The mice were then challenged with B16F1 cells on day 0. All mice received TRP-2180–188 plus CpG ODN-containing vaccines and IL-2 as described in A. Tumor growth was inhibited in control mice compared with CD8-depleted mice. A statistically significant difference (p < 0.001) occurred at the indicated (∗) time points (control n = 12, CD8-depleted n = 10).

Tumor growth inhibition mediated by TRP-2180–188 plus CpG ODN-containing vaccines combined with IL-2 is dependent on CD8+ T cells

The finding that the tumor growth inhibition mediated by peptide plus CpG ODN-containing vaccines administered with IL-2 was dependent on the presence of the MHC class I-presented peptide TRP-2180–188 indicated that CD8+ T cells were causing the antitumor response. To conclusively demonstrate this, we depleted CD8+ cells from one group of mice and left another group undepleted. Next, we treated both groups with vaccines consisting of TRP-2180–188 plus CpG ODN in IFA and administered IL-2 to both groups. We found that tumor growth inhibition was dependent on CD8+ T cells (Fig. 4⇑D).

CD8+ T cells elicited by a CpG ODN plus IL-2-containing vaccination regimen or vaccination regimens in which either CpG ODN or IL-2 were omitted have similar avidities

A vaccination regimen containing the combination of IL-2 plus CpG ODN elicited larger TRP-2180–188-specific CD8+ T cell responses than regimens in which either IL-2 or CpG ODN were omitted when T cell responses were measured using APCs pulsed with a wide range of TRP-2180–188 peptide concentrations (Fig. 5⇓, A–C). The avidity of vaccine-elicited CD8+ T cells has been defined as the percentage of the maximum peptide-specific CD8+ T cell response elicited by APCs pulsed with graded concentrations of peptide (34). When measured in this manner, the avidity of CD8+ T cells elicited by vaccination regimens containing both IL-2 and CpG ODN was not different from the avidity of CD8+ T cells elicited by vaccination regimens containing only CpG ODN or only IL-2 (Fig. 5⇓D).

FIGURE 5.
FIGURE 5.

TRP-2180–188-specific CD8+ T cell responses were measured by stimulating splenocytes from vaccinated mice ex vivo using EL4 cells pulsed with either 10 μM (A), 0.01 μM (B), or 0.001 μM (C) TRP-2180–188 peptide and then performing intracellular staining for IFN-γ. D, The normalized percentage of CD8+ T cells that were TRP-2180–188 specific was defined as the percentage of the maximum CD8+ T cell response for each vaccine category that was elicited by APCs pulsed with either 10, 0.01, or 0.001 μM TRP-2180–188 peptide. The maximum response for each vaccine category was defined as the response elicited by APCs pulsed with 10 μM TRP-2180–188 peptide. Equal numbers of splenocytes from each of four mice in each vaccine category were combined for this experiment. All mice were vaccinated with TRP-2180–188 plus CpG ODN vaccines and all mice received IL-2 as described in Fig. 4⇑A. This was one of two experiments with nearly identical results.

CpG ODN plus E749–57-containing vaccines plus systemic IL-2 eradicate TC-1 tumor cells

To demonstrate the antitumor efficacy of CpG ODN-containing vaccines combined with IL-2 in a different tumor model, we used the TC-1 fibroblast tumor cell line. TC-1 expresses the human papillomavirus E7 protein (29). Amino acid 49–57 of the E7 protein (E749–57) form an immunogenic H-2 Db-presented epitope (11). Mice were injected with TC-1 tumor cells and then 3 days later they were treated with a vaccination regimen that included E749–57 plus CpG ODN in IFA vaccines and systemic IL-2. This regimen produced E749–57-specific CD8+ T cell responses that were detected ex vivo by ICCS assay (Fig. 6⇓A). These experiments also demonstrated a dramatic inhibition of tumor growth (Fig. 6⇓B) and increased survival (Fig. 6⇓C) in E749–57-vaccinated mice compared with mice that were treated identically except that a negative control peptide, NP366–374, replaced E749–57 in their vaccines. Ten of 13 mice that received the regimen consisting of E749–57 plus CpG ODN in IFA vaccines and systemic IL-2 continue to survive tumor-free >2 mo after injection of TC-1 cells.

FIGURE 6.
FIGURE 6.

Vaccination with E749–57 plus CpG ODN-containing vaccines and administration of systemic IL-2 generated epitope-specific CD8+ T cell responses and led to eradication of E7-expressing TC-1 tumors. A, Mice were injected with TC-1 tumor cells on day −3. The mice were then vaccinated with E749–57 plus CpG ODN-containing vaccines on days 0, 3, 6, and 14. IL-2 was administered on days 7–9 and 15–18. E749–57-specific CD8+ T cell responses were detected ex vivo on day 20 by ICCS assay. The numbers on the plots give the percentage of CD8+ splenocytes from a representative E749–57-vaccinated mouse that produced IFN-γ in response to stimulation with E749–57 or the negative control peptide NP366–374. When one group of mice was treated as described in A and another group was treated identically except that the negative control peptide NP366–374 replaced E749–57 in the vaccines, epitope-specific inhibition of tumor growth (B) and increased survival (C) occurred in the mice that received vaccines containing E749–57 compared with mice that received vaccines containing NP366–374 (n = 13 mice/group).

The increase in vaccine-elicited TRP-2180–188-specific CD8+ T cell responses caused by IL-2 persists for at least 21 days after the final vaccination

Tumor-bearing mice received TRP-2180–188 plus CpG ODN in IFA vaccines and were treated with IL-2 or control injections. TRP-2180–188-specific CD8+ T cell responses were increased in mice that received IL-2 compared with mice that received control injections when TRP-2180–188-specific CD8+ T cell responses were measured 21 days after the final vaccination (Fig. 7⇓, A–C). All of the experiments described so far have measured splenic TRP-2180–188-specific CD8+ T cell responses. Addition of IL-2 to TRP-2180–188 plus CpG ODN in IFA vaccines also caused a dramatic increase in peripheral blood TRP-2180–188-specific CD8+ T cells (Fig. 7⇓D).

FIGURE 7.
FIGURE 7.

A, Enhancement of vaccine-elicited TRP-2180–188-specific CD8+ T cell responses by IL-2 persists 21 days after the final vaccination in tumor-bearing mice. Mice received TRP-2180–188 plus CpG ODN in IFA priming vaccinations on days 0, 3, and 6 and a boost vaccination on day 14. The mice received IL-2 or control injections on days 7–9 and 15–18. B16F1was injected the same day as the boost vaccination (day 14). Twenty-one days later, ICCS assay was performed. The plots show examples of the CD8+ T cell response in mice that received vaccines plus IL-2 and mice that received vaccines without IL-2. The percentage of CD3+CD8+ cells that produced IFN-γ is shown on each plot. B, TRP-2180–188-specific CD8+ T cell responses were measured by ICCS assay 21 days after boost vaccination in mice treated as described in A. The percentage of CD8+ T cells specific for TRP-2180–188 (B) and the absolute number of TRP-2180–188-specific CD8+ T cells (C) were increased by addition of IL-2 to TRP-2180–188 plus CpG ODN in IFA vaccines (n = 8 mice/group). D, Addition of IL-2 to TRP-2180–188 plus CpG ODN vaccines increased peripheral blood TRP-2180–188-specific CD8+ T cell responses. Mice were vaccinated and received IL-2 or control injections as described in A. ICCS assay was performed on peripheral blood cells 5 days after the final vaccination in the same manner that it was performed on splenocytes in all other experiments (n = 8 mice/group). E, Mice received TRP-2180–188 plus CpG ODN in IFA priming vaccinations on days 0, 3, and 6 and a boost vaccination on day 14. All mice were treated with IL-2 on days 7–9 and 15–18. One group of mice received vaccines that contained the HBC128–140“helper epitope” and another group was treated identically except that the HBC128–140 epitope was omitted. When the two groups were assessed by ICCS assay 30 days after the boost vaccination, there was not a significant difference in the percentage of CD8+ T cells specific for TRP-2180–188 or in the absolute number of TRP-2180–188-specific CD8+ T cells (F) (n = 8 mice/group).

A “helper epitope” did not enhance TRP-2180–188-specific memory CD8+ T cell responses generated by CpG plus IL-2-containing vaccination regimens

Experiments were conducted to directly assess the importance of the HBC128–140“helper epitope” in long-term TRP-2180–188-specific memory CD8+ T cell responses. These experiments did not demonstrate a significant difference between mice that received vaccines containing HBC128–140 or not containing HBC128–140 in the percentage of CD8+ T cells specific for TRP-2180–188 (Fig. 7⇑E) or the absolute number of TRP-2180–188-specific CD8+ T cells (Fig. 7⇑F) 30 days after the final vaccination.

Synergism between CpG ODN and IL-2 is evident when mice are vaccinated with long CPP

To demonstrate that synergism between CpG ODN and IL-2 occurs with vaccination using immunogens other than minimal MHC class I-binding peptides, we replaced the minimal MHC-binding peptides used in the rest of our experiments with a 21-aa peptide that is made up of a cell-penetrating moiety and the TRP-2180–188 peptide. This peptide is referred to as CPP-TRP-2 (32). We chose to use this peptide because it can penetrate the cell membrane of dendritic cells and then be presented on the dendritic cell surface where it can be recognized by CD8+ T cells (32).

Consistent with our previous findings, strong synergism between CpG ODN and IL-2 at enhancing vaccine-elicited CD8+ T cell responses was evident when vaccines contained the CPP-TRP-2 peptide (Fig. 8⇓). These results suggest that synergism between CpG ODN and IL-2 can increase CD8+ responses elicited by intracellularly processed Ags.

FIGURE 8.
FIGURE 8.

Synergism between CpG ODN and IL-2 was evident when mice received vaccines containing CPP-TRP-2. A, Mice were vaccinated with CPP-TRP-2 in IFA with or without CpG ODN on days 0, 3, 6, and 14. The mice received IL-2 or control injections on days 7–9 and 15–18. On day 19, TRP-2180–188-specific CD8+ T cell responses were measured by ICCS assay. Vaccines containing both CpG ODN and IL-2 elicited larger TRP-2180–188-specific CD8+ T cell responses as a percentage of total CD3+CD8+ splenocytes than regimens containing CpG ODN without IL-2, regimens containing IL-2 without CpG ODN, or regimens containing CPP-TRP-2 in IFA with neither CpG ODN nor IL-2 (n = 8/group). B, In the same mice described in A, vaccination regimens containing both CpG ODN and IL-2 generated a larger absolute number of TRP-2180–188-specific CD3+CD8+ splenocytes than regimens containing CpG ODN without IL-2, regimens containing IL-2 without CpG ODN, or regimens containing CPP-TRP-2 in IFA with neither CpG ODN nor IL-2 (n = 8/group).

Adding systemic IL-2 to TRP-2180–188 plus CpG ODN-containing vaccines increases the number of CD8+ T cells with TCR capable of binding TRP-2180–188-Kb tetramers

Our findings demonstrated that addition of IL-2 to TRP-2180–188 plus CpG ODN-containing vaccines dramatically increased CD8+ T cell responses as measured by intracellular cytokine staining for IFN-γ. Because this is a functional assay, the increase in TRP-2180–188-specific CD8+ T cells could have been due to an increase in the number of cells bearing TCRs capable of recognizing TRP-2180–188, or the addition of IL-2 could have increased the fraction of TRP-2180–188-specific CD8+ T cells that could produce IFN-γ without actually increasing the number of T cells bearing TCR that could recognize TRP-2180–188. We hypothesized that addition of IL-2 increased the number of CD8+ T cells with TCR that recognized TRP-2180–188. To test this hypothesis, we vaccinated two groups of mice with TRP-2180–188 plus CpG ODN in IFA and administered IL-2 to one of the groups and control injections to the other group. We measured vaccine-elicited, TRP-2180–188-specific CD8+ T cell responses directly ex vivo with TRP-2180–188-Kb tetramers (Fig. 9⇓A). Addition of IL-2 to TRP-2180–188 plus CpG ODN vaccines increased the number of CD8+ splenocytes capable of binding TRP-2180–188-Kb tetramers as a percentage of total CD8+ splenocytes (Fig. 9⇓B) or as an absolute number of CD8+ splenocytes (Fig. 9⇓C). These data demonstrate that addition of IL-2 to TRP-2180–188 plus CpG ODN-containing vaccines increased the number of CD8+ T cells with TCR that recognized TRP-2180–188. Addition of IL-2 to TRP-2180–188 plus CpG ODN in IFA vaccines caused a 32.8-fold increase in the mean percentage of CD8+ splenocytes that were TRP-2180–188-specific as measured by direct ex vivo analysis with TRP-2180–188-Kb tetramers (Fig. 9⇓B). The same mice in which TRP-2180–188-specific CD8+ T cell responses were measured using tetramers were also assessed by ICCS assay for TRP-2180–188-specific IFN-γ production. As measured by ICCS assay, a 12.6-fold increase in the mean percentage of CD8+ splenocytes that were TRP-2180–188 specific occurred when IL-2 was added to TRP-2180–188 plus CpG ODN in IFA vaccines (Fig. 9⇓D). Because a greater increase in TRP-2180–188-specific CD8+ T cell responses with addition of IL-2 to TRP-2180–188 plus CpG ODN-containing vaccines was detected when responses were measured by direct binding to tetramers than by the ICCS assay for IFN-γ, we concluded that most of the increase in TRP-2180–188-specific CD8+ T cell responses detected by the ICCS assay was due to an increase in the number of CD8+ T cells with TCR that recognized TRP-2180–188 and not to functional enhancement leading to increased IFN-γ production.

FIGURE 9.
FIGURE 9.

Direct quantitation of epitope-specific CD8+ T cells with TRP-2180–188-Kb tetramers demonstrated an enhancement of TRP-2180–188 plus CpG ODN in IFA vaccine responses by IL-2. A, Representative examples are shown of TRP-2180–188-Kb tetramer binding to CD8+ T cells from mice that received TRP-2180–188 plus CpG ODN in IFA vaccines and IL-2 or control injections as described in Fig. 7⇑A. TRP-2180–188-specific CD8+ T cell responses were measured 5 days after the final vaccination. An example of TRP-2180–188-Kb tetramer binding to cells from control-vaccinated mice that were vaccinated with NP366–374 plus CpG ODN in IFA and treated with IL-2 is also shown. The numbers on the plots refer to the fraction of CD8+ splenocytes that bound TRP-2180–188-Kb tetramers. In mice treated as described in A, IL-2 increased the fraction (B) and the absolute number (C) of TRP-2180–188-specific CD8+ splenocytes (n = 8 mice/group). D, T cells from the same mice described in Fig. 6⇑ were also analyzed by ICCS assay (n = 8/group).

TRP-2180–188 is a self-Ag. To determine whether addition of IL-2 to peptide plus CpG ODN-containing vaccines could also enhance responses to foreign Ags, we vaccinated two groups of mice with OVA257–264 plus CpG ODN in IFA and administered IL-2 to one of the groups and control injections to the other group. We measured vaccine-elicited, OVA257–264-specific CD8+ T cell responses directly ex vivo with OVA257–264-Kb tetramers (Fig. 10⇓A). Addition of IL-2 to the OVA257–264 plus CpG ODN-containing vaccines increased the number of CD8+ splenocytes capable of binding OVA257–264-Kb tetramers as a percentage of total CD8+ splenocytes (Fig. 10⇓B) or as an absolute number of CD8+ splenocytes (Fig. 10⇓C).

FIGURE 10.
FIGURE 10.

A, Representative examples are shown of ex vivo OVA257–264-Kb tetramer binding to CD8+ T cells from mice that received OVA257–264 plus CpG ODN in IFA priming vaccines on days 0, 3, and 6 and a boost vaccination on day 14. The mice received either IL-2 or control injections on days 7–9 and 15–18. OVA257–264-specific CD8+ T cell responses were measured with OVA257–264-Kb tetramers on day 19. An example of OVA257–264-Kb tetramer binding to cells from control-vaccinated mice that were vaccinated with gp10025–33 plus CpG ODN in IFA and treated with IL-2 is also shown. The numbers on the plots refer to the fraction of CD8+ splenocytes that bound OVA257–264-Kb tetramers. In mice treated as described in A, IL-2 increased the fraction (B) and the absolute number (C) of OVA257–264-specific CD8+ splenocytes (with IL-2 n = 9, no IL-2 n = 10). D, Enhancement of RSV M282–90 plus CpG ODN in IFA vaccination by IL-2 occurs in BALB/c mice. Mice were vaccinated with RSV M282–90 plus CpG ODN in IFA on days 0, 3, 6, and 14. The mice received either IL-2 or control injections on days 7–9 and 15–18. On day 19, RSV M282–90-specific CD8+ T cell responses were measured by RSV M282–90-Kd pentamers and by ICCS assay. IL-2 increased RSV M282–90-specific CD8+ T cell responses as measured by direct ex vivo quantitation with RSV M282–90-Kd pentamers (with IL-2 and no IL-2 n = 10). E, Ex vivo quantitation of RSV M282–90-specific CD8+ T cells by ICCS assay was performed on the same mice described in D. The ICCS assay detected a similar increase in vaccine-elicited RSV M282–90-specific responses as was detected by the RSV M282–90-Kd pentamers when IL-2 was added to RSV M282–90 plus CpG ODN in IFA vaccines.

Administration of IL-2 to BALB/c mice vaccinated with peptide plus CpG ODN-containing vaccines dramatically enhances epitope-specific CD8+ T cell responses

A series of experiments was conducted in which BALB/c mice were vaccinated with a peptide from the respiratory syncytial virus M2 protein (RSV M282–90) emulsified in IFA with CpG ODN. These experiments extend our previous results because the BALB/c strain is quite different in cytokine production and other immune characteristics from the C57BL/6 mice used in the rest of our experiments (35). Addition of IL-2 to RSV M282–90 plus CpG ODN-containing vaccines caused a 6.8-fold increase in the mean percentage of CD8+ splenocytes that were RSV M282–90 specific as measured by direct ex vivo analysis with RSV M282–90-Kd pentamers (Fig. 10⇑D) and a 5.1-fold increase in the mean percentage of CD8+ splenocytes that were RSV M282–90-specific of as measured by ICCS assay (Fig. 10⇑E). These data demonstrated that the increase in RSV-M282–90-specific CD8+ T cells detected by ICCS assay when IL-2 was added to RSV M282–90 plus CpG ODN-containing vaccines was due to an increase in the number of CD8+ T cells with TCR capable of recognizing the peptide included in the vaccine, because equivalent increases in RSV-M282–90-specific CD8+ T cells were detected by pentamer binding and by ICCS assay for IFN-γ.

Generation of epitope-specific CD8+ T cell responses by peptide plus CpG ODN-containing vaccines combined with exogenous IL-2 depends on endogenous IL-6

Because CpG ODN have been shown to make conventional CD4+ T cells resistant to the suppressive effects of Tregs by an IL-6-dependent mechanism (15), we hypothesized that IL-6 could be important in generating the large CD8+ T cell responses elicited by peptide plus CpG ODN-containing vaccines combined with exogenous IL-2. When we administered OVA257–264 plus CpG ODN in IFA vaccines and IL-2 to wild-type mice and IL-6-deficient mice, OVA257–264-specific responses were attenuated in the IL-6-deficient mice (Fig. 11⇓A). Type I IFNs have been shown to be important in generation of CD8+ T cell responses by CpG ODN-containing vaccines (36). When we administered RSV M282–90 plus CpG ODN in IFA vaccines and IL-2 to wild-type mice and to type I IFNR-deficient mice, the vaccine-elicited RSV M282–90-specific responses were not different (Fig. 11⇓B).

FIGURE 11.
FIGURE 11.

OVA257–264-specific CD8+ T cell responses elicited by OVA257–264 plus CpG ODN in IFA vaccines administered with IL-2 are abrogated in IL-6-deficient mice. A, Mice were vaccinated, IL-2 was administered, and tetramer staining was performed as described in Fig. 10⇑A. Compared with wild-type mice, IL-6-deficient mice generated smaller OVA257–264-specific CD8+ T cell responses. B, Mice were vaccinated, IL-2 was administered, and pentamer staining was performed as in Fig. 10⇑D. Type I IFNR-deficient mice generated RSV M282–90-specific CD8+ T cell responses that were not different from those detected in wild-type mice.

Discussion

We have demonstrated for the first time that CpG ODN and IL-2 synergize to dramatically increase the magnitude of peptide-vaccine-elicited CD8+ T cell responses (Figs. 2⇑, 4⇑, 7–10⇑⇑⇑⇑). The absolute number of epitope-specific CD8+ T cells increased up to 221-fold when exogenous IL-2 was added to a peptide plus CpG ODN vaccination regimen (Figs. 2⇑E, 4⇑B, 7⇑C, 9⇑C, and 10⇑C). Synergism between CpG ODN and IL-2 increased epitope-specific CD8+ T cell responses as measured by a functional assay for IFN-γ (Figs. 2⇑, 4⇑, 7⇑, 9⇑D, and 10⇑E), or as measured by direct ex vivo binding of the epitope-specific CD8+ T cells to peptide-MHC multimers (Figs. 9⇑, A–C, and 10⇑, A–D). The increase in vaccine-elicited CD8+ T cells caused by addition of IL-2 to TRP-2180–188 plus CpG ODN-containing vaccines persisted for at least 3 wk after the last vaccination (Fig. 7⇑, A–C). Peptide plus CpG ODN vaccines administered with IL-2 generated epitope-specific CD8+ T cell responses by a mechanism that involved endogenous IL-6 (Fig. 11⇑A).

Addition of IL-2 to TRP-2180–188 plus CpG ODN vaccines increased the number of TRP-2180–188-specific CD8+ T cells by a greater degree when measured by TRP-2180–188-Kb tetramers than when measured by the ICCS assay for IFN-γ production (Fig. 9⇑). Moreover, addition of IL-2 to RSV M282–90 plus CpG ODN vaccines increased the number of RSV M282–90-specific CD8+ T cells by a similar degree when measured by direct ex vivo binding to RSV M282–90-Kd pentamers or when measured by ICCS assay (Fig. 10⇑). Taken together, these data demonstrate that the main effect of IL-2 is an increase in the number of epitope-specific CD8+ T cells rather than an enhancement of functional status manifested by an enhanced ability to produce IFN-γ.

We observed epitope-specific inhibition of tumor growth by TRP-2180–188 plus CpG ODN in IFA vaccines only when the vaccines were combined with IL-2 (Fig. 1⇑B). Vaccination with TRP-2180–188 plus CpG ODN in IFA without IL-2 was ineffective at mediating epitope-specific inhibition of B16F1 growth (Fig. 1⇑A). In addition, TRP-2180–188 in IFA vaccines without CpG ODN did not cause epitope-specific tumor growth inhibition when combined with systemic IL-2 (Fig. 1⇑C). Tumor growth inhibition was demonstrated to be dependent on CD8+ T cells (Fig. 4⇑D), and TRP-2180–188 plus CpG ODN vaccines combined with IL-2 generated strikingly increased numbers of TRP-2180–188-specific CD8+ T cells compared with regimens with either CpG ODN or IL-2 omitted (Figs. 2⇑, C–E, 4⇑, A and B, and 7⇑). These data make the increased number of TRP-2180–188-specific CD8+ T cells with addition of IL-2 to TRP-2180–188 plus CpG ODN-containing vaccines the most likely reason that epitope-specific tumor growth inhibition was only observed when TRP-2180–188 plus CpG ODN vaccines were combined with IL-2.

Our tumor therapy experiments used wild-type mice and the highly aggressive, poorly immunogenic, TRP-2-expressing B16F1 melanoma. When B16F1 tumor-bearing mice were vaccinated with the negative control peptide OVA257–264 and CpG ODN in IFA and received systemic IL-2, TRP-2180–188-specific CD8+ T cell responses were not elicited. Generation of TRP-2180–188-specific CD8+ T cell responses depended on the presence of TRP-2180–188 in vaccines (Fig. 3⇑). This result shows that TRP-2180–188-specific CD8+ T cell responses were not generated by direct priming by B16F1 or cross-priming by tumor-infiltrating dendritic cells and confirms that B16F1 is a very poorly immunogenic tumor that is a difficult test for any CD8+ T cell-mediated therapy.

To our knowledge, the CD8+ T cell responses elicited by TRP-2180–188 plus CpG ODN-containing vaccines administered with IL-2 are the largest ever measured against this epitope by an ex vivo assay. The CD8+ T cell responses elicited by vaccines containing TRP-2180–188 plus CpG ODN administered with IL-2 were larger in magnitude than the responses elicited against this epitope by a whole tumor cell vaccine combined with CTLA-4 blockade and Treg depletion (37). The magnitude of responses obtained by vaccination with TRP-2180–188 plus CpG ODN-containing vaccines administered with IL-2 were larger than those elicited by recombinant viral vaccines encoding the TRP-2 protein (38).

Other investigators have shown that the same CpG ODN used in our work and CD40 agonists synergize to enhance CD8+ T cell responses elicited by OVA257–264 peptide vaccination. These investigators found that vaccine responses to the OVA257–264 peptide combined with CpG ODN and CD40 agonists were dependent on endogenous type I IFN (36). In contrast, we demonstrated that CD8+ T cell responses elicited by peptide plus CpG ODN-containing vaccines combined with IL-2 were not dependent on type I IFN (Fig. 8⇑B).

Although one previous study has shown that the antitumor activity of a vaccine regimen containing CpG ODN was dependent on endogenous IL-6 (39), our work is the first to demonstrate that the magnitude of epitope-specific CD8+ T cell responses elicited by CpG ODN-containing vaccines is dependent on endogenous IL-6 (Fig. 11⇑A). Other investigators have shown that the TLR ligands LPS and CpG ODN can make conventional CD4+ T cells resistant to the suppressive effects of Tregs by an IL-6-dependent mechanism. These same investigators went on to show an attenuation of CD4+ T cell responses elicited by a protein plus LPS plus IFA vaccine in IL-6-deficient mice. This attenuation of vaccine responses in IL-6-deficient mice was reversed by depletion of Tregs (15). Because CD8+ T cell responses elicited by peptide plus CpG ODN in IFA vaccines combined with exogenous IL-2 were attenuated in IL-6-deficient mice, IL-6 might also make CD8+ T cells resistant to suppression by Tregs.

One of the most important aspects of our work is the potential clinical relevance. It was recently shown in a clinical trial that the type-B CpG ODN, CpG 7909, dramatically increased CD8+ T cell responses when added to a Melan-A peptide in IFA vaccine (12). The CD8+ T cell responses detected in this clinical trial were some of the largest vaccine-elicited CD8+ T cell responses ever reported in humans. Systemic side effects in patients that received Melan-A peptide plus CpG 7909 in IFA vaccines were minimal. Like CpG 7909, the CpG ODN used in our work is also a type-B CpG ODN (13, 14). Our work suggests that addition of short courses of low to moderate doses of IL-2 to peptide plus CpG ODN 7909 vaccinations might cause dramatic increases in the magnitude of vaccine-elicited CD8+ T cell responses and might enhance the antitumor efficacy of these vaccines. The doses of IL-2 administered in our work were substantially less than those used in some other murine models (1, 24). In addition, synergism between CpG ODN and IL-2 is still evident at lower doses of both reagents (J. D. Kochenderfer, C. D. Chien, J. L. Simpson, and R. E. Gress, manuscript in preparation). Because IL-2 is already an approved drug, an extensive experience with dosages, administration schedules, and potential side-effects has been accumulated (5, 22, 40). A clinical trial of peptide plus CpG 7909 vaccination combined with IL-2 is feasible. In addition to peptide vaccines, other types of vaccines have been combined with CpG ODN (39, 41). IL-2 might be added to these vaccination regimens to determine whether the combination of CpG ODN and IL-2 could enhance vaccine-elicited, Ag-specific T cell responses. Our results demonstrating dramatic enhancement of CD8+ T cell responses against the viral epitope RSV M282–90 show that peptide plus CpG ODN vaccines combined with exogenous IL-2 can elicit large CD8+ T cell responses against viral Ags (Fig. 10⇑). Combining CpG ODN and IL-2 might be a useful strategy for generating antiviral T cell responses.

In conclusion, IL-2 synergizes with CpG ODN to dramatically increase vaccine-elicited CD8+ T cell responses. TRP-2180–188 plus CpG ODN in IFA vaccination was not an effective therapy for B16F1 melanoma unless IL-2 was also administered. Vaccine responses elicited by peptide plus CpG ODN vaccination combined with exogenous IL-2 were dependent on endogenous IL-6. Finally, addition of exogenous IL-2 to clinical antitumor and antiviral vaccination strategies that include CpG ODN is a promising area for future research.

Acknowledgments

We thank Krishna Komanduri for helpful discussion. We thank D. Simon and J. Hoover for excellent technical assistance.

Disclosures

The authors have no financial conflict of interest.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 This work was supported by intramural funding of the National Cancer Institute.

  • ↵2 Address correspondence and reprint requests to Dr. James N. Kochenderfer, National Institutes of Health, 10 Center Drive, Clinical Research Center 3-3288, Bethesda, MD 20892. E-mail address: kochendj{at}mail.nih.gov

  • ↵3 Abbreviations used in this paper: ODN, oligodeoxynucleotide; Treg, T regulatory cell; TRP, tyrosine-related protein; CPP, cell-penetrating peptide; HBC, hepatitis B core; RSV, respiratory syncytial virus; ICCS, intracellular cytokine staining; 7-AAD, 7-aminoactinomycin D.

  • Received March 14, 2006.
  • Accepted September 29, 2006.

References

  1. ↵
    Overwijk, W. W., M. R. Theoret, S. E. Finkelstein, D. R. Surman, L. A. de Jong, F. A. Vyth-Dreese, T. A. Dellemijn, P. A. Antony, P. J. Spiess, D. C. Palmer, et al 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198: 569-580.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    van Elsas, A., R. P. Sutmuller, A. A. Hurwitz, J. Ziskin, J. Villasenor, J. P. Medema, W. W. Overwijk, N. P. Restifo, C. J. Melief, R. Offringa, J. P. Allison. 2001. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194: 481-489.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Davila, E., R. Kennedy, E. Celis. 2003. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 63: 3281-3288.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327.
    OpenUrlCrossRefPubMed
  6. ↵
    Rosenberg, S. A., J. C. Yang, N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
    OpenUrlCrossRefPubMed
  7. ↵
    Weber, J., V. K. Sondak, R. Scotland, R. Phillip, F. Wang, V. Rubio, T. B. Stuge, S. G. Groshen, C. Gee, G. G. Jeffery, et al 2003. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97: 186-200.
    OpenUrlCrossRefPubMed
  8. ↵
    Nielsen, M. B., V. Monsurro, S. A. Migueles, E. Wang, A. Perez-Diez, K. H. Lee, U. Kammula, S. A. Rosenberg, F. M. Marincola. 2000. Status of activation of circulating vaccine-elicited CD8+ T cells. J. Immunol. 165: 2287-2296.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Miconnet, I., S. Koenig, D. Speiser, A. Krieg, P. Guillaume, J. C. Cerottini, P. Romero. 2002. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 168: 1212-1218.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Davila, E., E. Celis. 2000. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J. Immunol. 165: 539-547.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Zwaveling, S., S. C. Ferreira Mota, J. Nouta, M. Johnson, G. B. Lipford, R. Offringa, S. H. van der Burg, C. J. Melief. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169: 350-358.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Speiser, D. E., D. Lienard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A. M. Krieg, J. C. Cerottini, P. Romero. 2005. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115: 739-746.
    OpenUrlCrossRefPubMed
  13. ↵
    Krieg, A. M.. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
    OpenUrlCrossRefPubMed
  14. ↵
    Ballas, Z. K., A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, G. J. Weiner. 2001. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167: 4878-4886.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Pasare, C., R. Medzhitov. 2003. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Smith, K. A.. 1988. Interleukin-2: inception, impact, and implications. Science 240: 1169-1176.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Blattman, J. N., J. M. Grayson, E. J. Wherry, S. M. Kaech, K. A. Smith, R. Ahmed. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9: 540-547.
    OpenUrlCrossRefPubMed
  18. ↵
    Rubinstein, M. P., A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders, D. J. Cole. 2002. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J. Immunol. 169: 4928-4935.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Oh, S., J. A. Berzofsky, D. S. Burke, T. A. Waldmann, L. P. Perera. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. USA 100: 3392-3397.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Chen, W., V. A. Reese, M. A. Cheever. 1990. Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2. J. Immunol. 144: 3659-3666.
    OpenUrlAbstract
  21. ↵
    Nguyen, C. L., M. L. Salem, M. P. Rubinstein, M. Demcheva, J. N. Vournakis, D. J. Cole, W. E. Gillanders. 2003. Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine 21: 2318-2328.
    OpenUrlCrossRefPubMed
  22. ↵
    Slingluff, C. L., Jr, G. R. Petroni, G. V. Yamshchikov, S. Hibbitts, W. W. Grosh, K. A. Chianese-Bullock, E. A. Bissonette, D. L. Barnd, D. H. Deacon, J. W. Patterson, et al 2004. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol. 22: 4474-4485.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Shimizu, K., R. C. Fields, M. Giedlin, J. J. Mule. 1999. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA 96: 2268-2273.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Eggert, A. O., J. C. Becker, M. Ammon, A. D. McLellan, G. Renner, A. Merkel, E. B. Brocker, E. Kampgen. 2002. Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur. J. Immunol. 32: 122-127.
    OpenUrlCrossRefPubMed
  25. ↵
    Seliger, B., U. Wollscheid, F. Momburg, T. Blankenstein, C. Huber. 2001. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 61: 1095-1099.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Bloom, M. B., D. Perry-Lalley, P. F. Robbins, Y. Li, M. el-Gamil, S. A. Rosenberg, J. C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185: 453-459.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, G. Kohler. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342.
    OpenUrlCrossRefPubMed
  28. ↵
    Muller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Lin, K. Y., F. G. Guarnieri, K. F. Staveley-O’Carroll, H. I. Levitsky, J. T. August, D. M. Pardoll, T. C. Wu. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56: 21-26.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Aung, S., B. S. Graham. 2000. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo. J. Immunol. 164: 3487-3493.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Mata, M., P. J. Travers, Q. Liu, F. R. Frankel, Y. Paterson. 1998. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J. Immunol. 161: 2985-2993.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Wang, R.-F., H. Y. Wang. 2002. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotech. 20: 149-154.
    OpenUrlCrossRefPubMed
  33. ↵
    Hernandez, J., A. Ko, L. A. Sherman. 2001. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J. Immunol. 166: 3908-3914.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Bullock, T. N. J., D. W. Mullins, V. H. Engelhard. 2003. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J. Immunol. 170: 1822-1829.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Mills, C. D., K. Kincaid, J. M. Alt, M. J. Heilman, A. M. Hill. 2000. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164: 6166-6173.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Ahonen, C. L., C. L. Doxsee, S. M. McGurran, T. R. Riter, W. F. Wade, R. J. Barth, J. P. Vasilakos, R. J. Noelle, R. M. Kedl. 2004. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199: 775-784.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Sutmuller, R. P., L. M. van Duivenvoorde, A. van Elsas, T. N. Schumacher, M. E. Wildenberg, J. P. Allison, R. E. Toes, R. Offringa, C. J. Melief. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194: 823-832.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    De Palma, R., I. Marigo, F. Del Galdo, C. De Santo, P. Serafini, S. Cingarlini, T. Tuting, J. Lenz, G. Basso, G. Milan, et al 2004. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor α usage by melanoma-specific CD8+ T lymphocytes. Cancer Res. 64: 8068-8076.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Daftarian, P., G. Y. Song, S. Ali, M. Faynsod, J. Longmate, D. J. Diamond, J. D. Ellenhorn. 2004. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res. 64: 5407-5414.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Woodson, E. M., K. A. Chianese-Bullock, C. J. Wiernasz, E. A. Bissonette, W. W. Grosh, P. Y. Neese, P. K. Merrill, D. L. Barnd, G. R. Petroni, C. L. Slingluff, Jr. 2004. Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine. J. Immunother. 27: 380-388.
    OpenUrlCrossRefPubMed
  41. ↵
    Tritel, M., A. M. Stoddard, B. J. Flynn, P. A. Darrah, C. Y. Wu, U. Wille, J. A. Shah, Y. Huang, L. Xu, M. R. Betts, et al 2003. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J. Immunol. 171: 2538-2547.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section